Identifying and managing morphologic complications of HIV and HAART

AIDS Reader

Volumn 12, Issue 3, 2002, Pages 114-125

  Currier, Judith ^a   Carpenter, Charles ^a   Daar, Eric ^a   Kotler, Donald ^a   Wanke, Christine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HAART; HIV AIDS; Lipodystrophy; Metabolic complications; Wasting

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; METFORMIN; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; TROGLITAZONE; ZIDOVUDINE;

ANTHROPOMETRY; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPOATROPHY; LIPOHYPERTROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PLASTIC SURGERY; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME; WASTING SYNDROME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DENSITOMETRY, X-RAY; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; LIPODYSTROPHY;

EID: 0036198917     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. HIV-associated wasting in the HAART era: Guidelines for assessment, diagnosis, and treatment
2. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection
3. Antiretroviral therapy and the lipodystrophy syndrome
4. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia
5. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance
6. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
7. Dual-energy x-ray absorptiometry in the early diagnosis of body shape changes in patients with HIV infection treated with nucleoside reverse transcriptase inhibitors and naive to protease inhibitors
8. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
9. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome
10. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
11. Body fat assessed from total body density and its estimation from skinfold thickness: Measurements on 481 men and women aged from 16 to 72 years
12. Anthropometric assessment of fat-free body mass
13. Bioelectrical impedance analysis in body composition measurement: National Institutes of Health technology assessment conference statement, December 12-14, 1994
14. Fat-free mass in chronic illness: Comparison of bioelectrical impedance and dual-energy x-ray absorptiometry in 480 chronically ill and healthy subjects
15. Techniques used in the measurement of body composition: An overview with emphasis on bioelectrical impedance analysis
16. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease
17. Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment
18. Assessment of intracellular water by whole body bioelectrical impedance and total body potassium in HIV-positive patients
19. Comparison of total body potassium with other techniques for measuring LBM in men and women with AIDS wasting
20. Epidemiological and clinical aspects of the metabolic complications of HIV infection: The fat redistribution syndrome
21. Measurement of total-body fat by underwater weighing: New insights and uses for old method
22. Monitoring changes in fat-free mass in HIV-positive men with hypertestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy
23. Use of dual-energy x-ray absorptiometry in body composition studies: Not yet a gold standard
24. Appendicular skeletal muscle mass: Measurement by dual-photon absorptiometry
25. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging
26. Skeletal muscle mass: Evaluation of neutron activation and dual-energy X-ray absorptiometry methods
27. Fat redistribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
28. Comparison of abdominal fat distribution in HIV+ patients, with and without clinical fat redistribution and HIV-patients, using computed tomography (CT)
29. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: A prospective cohort study
30. Abnormalities of body composition, lipids associated with HAART: Pathogenesis, clinical manifestations, and case definitions
31. Interactions among sex, HIV infection, and fat redistribution
32. Relative influence of sex, race, environment, and HIV infection on body composition in adults
33. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
34. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
35. A prospective open-label pilot trial of a maintenance nevirapine (NVP)-containing regimen in patients with undetectable viral loads (VL) on protease inhibitor (PI) regimens for at least 6 months
36. Identification of fat redistribution/metabolic anomalies in a cohort treated by 2 NRTIs + 1 PI, and absence of significant modification following PI substitution
37. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2 NRTI/PI to 2 NRTI/abacavir (French Substudy, CNA30017)
38. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors (PI) to efavirenz (EFV)
39. Evaluation of lipodystrophy syndrome and lipid profile in HIV patients after switching from protease inhibitors to efavirenz
40. Impact of switching from HIV-1 protease inhibitors (PI) to efavirenz (EFV) in patients with lipodystrophy
41. A novel use of abacavir to simplify therapy in PI experienced patients successfully treated with HAART: CAN 30017
42. A randomized, multicenter study of protease inhibitor (PI) substitution in aviremic patients with antiretroviral (ARV) lipodystrophy syndrome
43. Reversibility of peripheral fat wasting (lipodystrophy) on stopping stavudine therapy
44. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection: Interim analysis
45. The use of growth hormone (Serostim) in patients with HIV-associated adipose redistribution syndrome (HARS)
46. Treatment of HAART associated fat accumulation disease with recombinant human growth hormone: Results of a randomized double blind placebo controlled cross-over trial
47. The effects of recombinant human growth hormone on glucose metabolism and body compositionin HIV-positive subjects with fat accumulation syndromes
48. Potential of recombinant human growth hormone in HIV-associated adipose redistribution syndrome
49. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV
50. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
51. Protease inhibitor-associated hyperglycaemia
52. Diabetes and hyperglycemia in patients receiving protease inhibitors
53. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
54. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
55. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients
56. Metabolic effects of indinavir in healthy HIV-seronegative men
57. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
58. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
59. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
60. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial
61. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) therapy
62. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
63. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use
64. Liposuction for protease-inhibitor-associated lipodystrophy
65. The effects of polylactic acid as therapy for lipodystrophy of the face